Bristol-Myers Squibb

Director, WW Portfolio Strategy, WW Medical Cell Therapy

Madison, New Jersey, United States

Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical, Biotechnology, HealthcareIndustries

Requirements

Candidates should possess a Bachelor’s degree and demonstrate at least 10 years of experience in portfolio strategy, preferably within the pharmaceutical or biotechnology industry, with a strong focus on medical cell therapy. They should have a proven track record of building and managing strategic relationships with external stakeholders, including academic institutions, industry leaders, and advocacy groups. Strong communication and presentation skills are essential, along with the ability to influence policy and regulatory decisions.

Responsibilities

This Director will develop and deliver presentations, reports, and communication materials to external audiences, establishing and maintaining strong relationships with external partners such as academic institutions, professional societies, and patient advocacy groups. The role involves collaborating with internal and external stakeholders to influence policy, engaging with government agencies and advocacy groups, coordinating leadership engagements, and building regular insights reporting for senior management. Furthermore, the Director will collaborate with internal teams and congress management to ensure excellence in execution with congress strategies including internal and external communications and TLE management.

Skills

Portfolio Strategy
Strategic Relationships
Communication
Presentation
Policy Influence
Regulatory Decisions
Stakeholder Management
Government Relations
Advocacy Groups
Insights Reporting
Congress Management
Internal Communications
TLE Management

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Key Metrics

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI